Keystone Biologicals Acquired by BioIVT for Portfolio Expansion

Pharmaceutical Technology Editors

The acquisition will expand BioIVT’s disease-state portfolio by volume and product range.

BioIVT announced that it acquired Keystone Biologicals, a disease-state plasma, sera, and controls supplier, to expand its disease-state portfolio by volume and product range. Financial details about the acquisition were not disclosed.

According to an Aug. 6, 2019 press release, Keystone Biologicals comes equipped with an in-house laboratory that characterizes raw material using testing formats including the client’s own test kits. This ensures that clients do not spend time and money evaluating material that does not meet their study requirements. The company also holds autoimmune, serology and virology, immunology, and tumor marker research samples, along with liquid-stable controls, standards, and calibrators for use with stock or custom-produced diagnostic kits.

"With the addition of Keystone Biologicals, BioIVT broadens its product offerings and better supports clients in the in-vitro diagnostic (IVD) market," said BioIVT CEO Jeffrey Gatz, in the press release.

"In BioIVT, we have found a like-minded partner whose desire to provide the highest quality research samples and customized products and services to satisfy client needs equals our own,” said Keystone Biologicals President Darren Lowenthal, in the press release. “We are delighted to be joining BioIVT and look forward to working together for the benefit of all our clients.”

Source: BioIVT